NCT01572519 - A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2012

Primary Completion Date

August 13, 2013

Study Completion Date

August 13, 2013

Conditions

Relapsed or Refractory Hodgkin Lymphoma

Interventions

DRUG

Phase 1, Cohort 1

Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 1, Cohort 2

Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 1, Cohort 3

Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 1, Cohort 4

Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 2

JNJ-40346527 at the recommended dose determined in Phase 1

Trial Locations (4)

Lille

Villejuif

Cologne

Würzburg

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY